Lung Stent Market Size & Share 2026-2035

Lung Stent Market Size

The global lung stent market was valued at USD 175.9 million in 2025 and is projected to reach USD 432.5 million by 2035, expanding at a CAGR of 9.5% from 2026 to 2035. According to the latest report published by Global Market Insights Inc., the market reaches USD 191.5 million in 2026. Lung stents, also called airway stents, are endoscopically implanted tubular prostheses that restore or maintain patency in obstructed tracheal, bronchial, and laryngeal airways. The market includes silicone, metallic, and hybrid devices sold for adult and pediatric care across hospital, ambulatory surgical center (ASC), and other clinical settings. It excludes vascular, biliary, and esophageal stents, diagnostic bronchoscopy equipment, and accessories sold without a stent.

The addressable market follows the clinical burden of malignant obstruction, chronic airway disease, post-infectious stenosis, and post-intubation injury rather than a single procedure-volume cycle. Lung cancer produced an estimated 2.5 million new cases and 1.8 million deaths globally in 2022, sustaining demand for palliative tracheobronchial intervention in advanced disease. ^[1] Chronic obstructive pulmonary disease (COPD) adds a separate source of demand: more than 80 million people in Europe were affected in the 2025 European Respiratory Society assessment.^[2] The commercial consequence is a mix of urgent oncology procedures, benign-disease reconstruction, and repeat-management cases, each requiring different material, radial-force, and retrieval characteristics.

Market revenue advanced from USD 137.47 million in 2022 to USD 161.72 million in 2024, a historic CAGR of 8.47%. Revenue reaches USD 191.51 million in 2026 and increases to USD 271.79 million in 2030 before reaching USD 432.47 million in 2035. The forecast incorporates expanding access to interventional pulmonology, wider use of flexible-bronchoscopy delivery systems, and an aging population in high-growth regions. It does not assume commercial approval of biodegradable airway stents, so successful clearance of temporary-support platforms would represent upside rather than an embedded forecast assumption.

Pricing remains differentiated by material and care setting. Silicone devices generally sell at lower price points than nitinol self-expandable metallic stents, while covered and specialized configurations command a premium because they address tissue ingrowth, migration, or difficult anatomy. North American reimbursement and premium OEM positioning support higher average selling prices. Asia Pacific contributes faster unit growth but has more price-sensitive public procurement and a larger domestic manufacturing base.

Key Drivers

Lung cancer burden and malignant airway obstruction

Lung cancer creates the most direct demand pathway because tumor growth and extrinsic compression can produce acute central-airway obstruction requiring prompt restoration of lumen patency. The intervention is not interchangeable with systemic treatment when respiratory compromise is immediate. That clinical urgency favors established platforms with familiar delivery systems, hospital training support, and broad configuration ranges. It also keeps tracheal devices at the center of market revenue even as bronchial procedures expand.

COPD and post-tuberculosis airway stenosis

COPD and post-tuberculosis stenosis diversify demand away from oncology. These conditions increase the importance of removability, secretion management, and staged intervention, which supports silicone and selected covered-device categories. WHO reported that approximately 1.25 million children aged 0–14 years fell ill with tuberculosis in 2023, reinforcing the pediatric relevance of post-infectious airway management. ^[3] The second-order effect is a higher premium on sizing precision and specialized physician experience, not merely a larger device volume pool.

Minimally invasive flexible-bronchoscopy adoption

Flexible-bronchoscopy delivery changes the economics of selected procedures. Through-the-scope and over-the-wire self-expanding systems reduce dependence on rigid bronchoscopy for eligible cases, making ASC deployment more feasible. This broadens access and improves procedure throughput, but ASC purchasing also increases pressure on device price and delivery-system simplicity. Manufacturers therefore compete on workflow fit as much as on radial-force specifications.

Innovation in covered, biodegradable, and customized devices

Product innovation expands the clinical envelope. Fully covered stents seek to limit tissue ingrowth, custom designs address difficult airway geometry, and research into biodegradable devices targets temporary-support indications. These approaches do not eliminate the need for hospital expertise. They redistribute value toward manufacturers that can pair a specialized device with clinical education and reliable procedural support.

Key Restraints

Alternative airway therapies without permanent stent implantation

Laser bronchoscopy, cryotherapy, endobronchial brachytherapy, and balloon dilation can reduce the need for an implanted stent in selected cases. These options restrain revenue where obstruction can be managed without durable structural support. The choice depends on anatomy, disease progression, expected dwell time, and physician judgment. Stent suppliers therefore need to demonstrate a clinical advantage in the patient subsets where patency cannot be maintained by ablation or dilation alone.

Regulatory evidence and market-authorization burden

Regulation imposes a second constraint. U.S. pathways can involve 510(k), De Novo, or PMA review, while European airway devices face EU MDR Class IIb conformity requirements. The burden extends beyond initial clearance to clinical evidence, quality systems, post-market surveillance, and distributor readiness. This favors established manufacturers with regulatory infrastructure and makes early commercial scale more difficult for novel-material entrants.

Migration, granulation tissue, and infection-related complications

Complication management remains a commercial and clinical limitation. Migration, granulation tissue formation, mucus plugging, and infection can trigger repeat bronchoscopy and influence device selection. The unresolved tradeoff between radial force, conformability, coverage, and retrievability explains why no single material displaces every alternative. It also supports continued demand for specialist silicone, covered-metal, and custom platforms.

Lung Stent Market Segment Analysis

By Product 

Tracheal stents generated USD 121.52 million in 2025, equal to 69.1% of global revenue, and will reach USD 294.97 million by 2035 at a 9.33% CAGR. Their scale reflects the severity of central-airway obstruction in malignant compression, post-intubation stenosis, tracheomalacia, and post-reconstruction strictures. Boston Scientific’s Ultraflex™ and TaeWoong Medical’s Niti-S™ illustrate the role of self-expanding metallic platforms in urgent tracheal management, while Novatech’s DUMON® and Hood Laboratories’ Montgomery T-tubes retain value where removability and reconstructive care matter. Product breadth is commercially important because tracheal lesions vary markedly in length, diameter, and need for coverage.

Bronchial stents held USD 45.61 million in 2025 and will be the fastest-growing product category at a 9.81% CAGR, reaching USD 115.62 million by 2035. Growth follows greater ability to reach main, lobar, and selected segmental bronchi through flexible bronchoscopy. Micro-Tech’s Y-shaped and J-shaped configurations, alongside Stening and Novatech carinal designs, address cases where the carina or both main bronchi require support. By 2030, bronchial growth will depend on manufacturers’ ability to improve conformability without increasing migration or compromising secretion clearance.

Laryngeal stents represented USD 8.76 million in 2025, or 5.0% of revenue, and will reach USD 21.88 million by 2035 at a 9.65% CAGR. These devices address post-surgical, traumatic, congenital, and post-radiation laryngeal stenosis. Hood Laboratories and Stening contribute relevant silicone and laryngeal-adjacent product options. The segment remains smaller because its indication set is specialized, but it has a distinct value proposition in airway reconstruction where preserving laryngeal function can avoid more extensive intervention.

By Device Type 

Self-expandable devices held USD 137.71 million in 2025, or 78.3% share, and will reach USD 341.31 million by 2035 at a 9.56% CAGR. Nitinol systems such as Ultraflex™, AERO®, AEROmini®, Niti-S™, HANAROSTENT®, and BONASTENT® provide continuous radial force and can conform to irregular lumens. Their delivery through flexible bronchoscopy creates a procedural advantage in selected hospital and ASC cases. Covered configurations add a barrier against tissue ingrowth, making the device category relevant to extended-dwell malignant-obstruction management.

Balloon-expandable stents accounted for USD 38.18 million in 2025 and will reach USD 91.16 million by 2035 at a 9.15% CAGR. They provide controlled final-diameter expansion where precision outweighs the convenience of spontaneous deployment. This makes them relevant in select pediatric, post-surgical, and anatomically stable settings. Renata Medical’s Minima system demonstrates balloon-expandable pediatric stent engineering but is a vascular device and is excluded from airway market sizing. The airway category’s slower growth reflects the broader fit of self-expandable platforms for dynamic and compressed airways.

By Material 

Silicone stents led the market with USD 97.11 million in 2025, equal to 55.2% share, and will reach USD 241.16 million by 2035 at a 9.58% CAGR. The DUMON® system, Montgomery T-tubes, and Stening’s straight, hourglass, and Y-shaped silicone platforms retain clinical relevance because silicone is removable and suited to benign disease and temporary reconstruction. External studs and specialized geometry help address migration risk. The segment’s leadership shows that material selection remains driven by retrieval requirements and airway biology, not only by delivery convenience.

Metal stents generated USD 70.91 million in 2025, or 40.3% share, and will reach USD 172.68 million by 2035. Nitinol will outpace stainless steel, growing at 9.89% versus 8.99%, because superelasticity supports collapse into lower-profile delivery systems and re-expansion in irregular airways. Cook-Z® retains a role in malignant obstruction, while Ultraflex™, Niti-S™, HANAROSTENT®, and BONASTENT® demonstrate the breadth of the nitinol category. The material shift is operational: flexible-bronchoscopy compatibility improves procedure workflow and enables more ASC-suitable cases.

Hybrid stents represented USD 7.87 million in 2025 and will reach USD 18.63 million by 2035 at a 9.06% CAGR. Covered-metal systems such as AERO® and selected TaeWoong and Micro-Tech products seek to combine radial force with an anti-ingrowth barrier. Peytant’s AMStent® advances the same design logic through an amnion-derived covering. Hybrid devices remain a small category, but their innovation intensity is high because complication mitigation is an unmet requirement across long-dwell stenting.

By Patient 

Adult applications accounted for USD 115.86 million in 2025, or 65.9% share, and will reach USD 288.31 million by 2035 at a 9.61% CAGR. Lung cancer, COPD-related airway collapse, prolonged-intubation injury, and thoracic-surgery complications make adults the central demand base. Product selection often centers on malignant obstruction, where Ultraflex™, Cook-Z®, AERO®, and Niti-S™ configurations provide procedural options. Aging populations in North America, Europe, and Asia Pacific will expand the number of patients requiring advanced airway intervention through 2035.

Pediatric applications generated USD 60.03 million in 2025 and will reach USD 144.16 million by 2035 at a 9.21% CAGR. Congenital stenosis, post-infectious narrowing, and growth-dependent anatomy require specialized sizing, careful material selection, and experienced centers. Montgomery T-tubes and tailored silicone systems remain relevant where future removal or revision is anticipated. Pediatric demand will preserve a specialist market even as adult oncology remains the larger revenue driver.

By End Use 

Hospitals held USD 115.12 million in 2025, equal to 65.5% share, and will reach USD 287.61 million by 2035 at a 9.65% CAGR. Rigid bronchoscopy, complex Y-stent deployment, pediatric interventions, urgent malignant obstruction, and post-procedural monitoring anchor this channel. Hospital purchasing also supports the first adoption of newer platforms because multidisciplinary teams can evaluate clinical fit and manage complications. The hospital channel will remain the principal entry point for complex and high-acuity cases.

ASCs generated USD 41.31 million in 2025 and will reach USD 108.96 million by 2035 at a 10.24% CAGR, the highest end-use rate. Low-profile self-expanding devices such as AEROmini®, Ultraflex™, and other flexible-bronchoscopy systems make selected procedures viable outside the inpatient setting. This transition lowers total procedural intensity for stable patients, but it does not remove the need for hospital referral pathways when anatomy, anesthesia, or risk is complex. By 2030, ASC growth will increase the value of streamlined delivery systems and predictable procurement.

Other end users, including specialty respiratory clinics, pulmonology outpatient practices, and long-term-care settings, accounted for USD 19.46 million in 2025. The segment will reach USD 35.91 million by 2035 at a 6.34% CAGR. Its smaller role reflects concentration of primary implantation in hospitals and ASCs. These settings contribute mainly through follow-up, monitoring, and coordinated chronic-airway care.

Lung Stent Market Regional Analysis

North America led the market with USD 75.84 million in 2025, representing 43.1% share, and will reach USD 174.80 million by 2035 at an 8.71% CAGR. The U.S. accounted for USD 68.88 million in 2025 and will reach USD 160.64 million by 2035, while Canada accounted for USD 6.97 million and will reach USD 14.16 million. The American Cancer Society estimates 229,410 new U.S. lung cancer cases and 124,990 deaths in 2026.^[4] Established interventional-pulmonology infrastructure, reimbursement, and domestic presence from Boston Scientific, Cook, Merit Medical, Hood Laboratories, and Peytant support market leadership. Canada’s single-payer procurement environment creates greater price sensitivity and slower expansion.

Europe generated USD 46.78 million in 2025, or 26.6% share, and will reach USD 112.04 million by 2035 at a 9.13% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands comprise the covered country set. The UK recorded approximately 50,200 new lung cancer cases annually during 2021–2022. ^[5] Europe also supplies specialized stent capacity through Novatech in France, Endo-Flex in Germany, and Stening’s European presence. EU MDR Regulation 2017/745 raises evidence and conformity demands for Class IIb airway devices, increasing barriers for new entrants but favoring companies with established quality and post-market systems.

Asia Pacific held USD 38.38 million in 2025, equal to 21.8% share, and will be the fastest-growing region at a 10.74% CAGR, reaching USD 106.47 million by 2035. China, Japan, India, Australia, and South Korea form the regional scope. UNFPA projects that one in four people in Asia and the Pacific will be older than 60 by 2050, with the older population reaching roughly 1.3 billion.^[6] China’s growth is supported by Micro-Tech and Health Microport Medical, which improve domestic availability and pricing. South Korea adds globally distributed stent capacity through TaeWoong Medical, M.I.Tech, and Standard Sci Tech. Japan supports premium-device adoption, while India expands as private hospital investment broadens pulmonary-intervention capability.

Latin America generated USD 8.85 million in 2025 and will reach USD 23.92 million by 2035 at a 10.43% CAGR. Brazil, Mexico, and Argentina are the covered markets. Latin America and the Caribbean had 91.5 million people aged 60 years or older in 2023, equivalent to 13.9% of the population. ^[7] Brazil’s private healthcare sector and expanding bronchoscopy infrastructure support demand, while Argentina contributes a manufacturing presence through Stening. The region’s higher growth rate reflects earlier-stage access to advanced airway intervention and continued need for cost-sensitive solutions.

Middle East and Africa generated USD 6.04 million in 2025 and will reach USD 15.24 million by 2035 at a 9.70% CAGR. South Africa, Saudi Arabia, and the UAE are the covered markets. Saudi Arabia and the UAE support the region’s highest-value demand through specialty-hospital investment and expanding minimally invasive pulmonary-care capability. South Africa remains the principal sub-Saharan clinical-infrastructure center. The regional limitation is uneven access to bronchoscopy expertise and advanced care, which restricts penetration despite rising respiratory-disease need.

Lung Stent Market Share & Competitive Landscape

The top five companies-Boston Scientific, Cook Group, Merit Medical, Micro-Tech (Nanjing), and TaeWoong Medical-collectively held approximately 65% of global revenue in 2025. Boston Scientific held the leading individual position through the Ultraflex™ platform and global clinical-commercial reach. The remaining share is dispersed among silicone specialists, regional manufacturers, covered-stent innovators, and client-retained reference companies outside the sizing model. Peytant’s FDA De Novo clearance for AMStent® in October 2024 introduced an amnion-covered airway-stent platform and established a Class II classification under 21 CFR 868.3721.^[8]

Boston Scientific competes through Ultraflex™ covered and uncovered nitinol self-expanding tracheobronchial stents. Cook Group maintains a major malignant-obstruction position with the stainless-steel Gianturco-Rösch Cook-Z® Tracheobronchial Stent and Introducer Set. Merit Medical’s AERO® and AEROmini® fully covered nitinol systems originated through the Endotek acquisition, not Endo-Flex. Their low-profile delivery supports flexible-bronchoscopy workflows. Micro-Tech offers tracheal, bronchial, Y-shaped, J-shaped, and hybrid platforms across more than 70 countries, supporting its Asia Pacific strength. TaeWoong Medical’s Niti-S™ line combines a broad endoscopy portfolio with global tracheobronchial distribution.^{[9]Cook Medical, *Cook-Z® Tracheobronchial Stent and Introducer Set*, cookmedical.com}

Recent Industry Developments

May 2026: Everis Medical completed its acquisition of Hood Laboratories, which now operates as a division of Everis Medical. The transaction brings specialized silicone airway-stent capability into a broader airway-management portfolio.

October 2024: Peytant Solutions received FDA De Novo clearance for AMStent®, an amnion-covered tracheobronchial stent for adult malignant strictures. The decision established a Class II category under 21 CFR 868.3721 and provides a regulatory reference point for future biologically surfaced devices.